One study reported that pediatric CBF fusion AML patients with both CSF3R and KIT mutations had worse outcomes than those with either mutation alone did, which aligns with our observation that targeting KIT might have helped some of our CBF‐rearranged/CSF3R patients [21]. Here, CSF3R is linked to acute myeloid leukemia.